Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT04574648
Other study ID # H18-01332_1
Secondary ID
Status Not yet recruiting
Phase N/A
First received
Last updated
Start date March 1, 2021
Est. completion date July 31, 2024

Study information

Verified date November 2020
Source University of British Columbia
Contact Jeffrey P Hau, MSc
Phone 6048754111
Email jeffrey.hau@ubc.ca
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Repeat non-adherence to medications is a common cause of preventable adverse drug events. Health information technologies have the potential to improve information continuity. However, they rarely interoperate to ensure providers can view non-adherence information documented in other systems. The investigators designed ActionADE to enable rapid documentation of adverse drug events, including non-adherence, and communicate the information across health sectors by integrating ActionADE with legacy systems. The investigators will leverage ActionADE's implementation to conduct a randomized trial on patients diagnosed with an adverse events due to non-adherence. This study will take place in Vancouver, British Columbia, Canada.


Description:

Medication use is rising due to an aging population and expanding treatment indications for chronic diseases. Simultaneously, adverse drug events-harmful and unintended events related to medication use or misuse-have increased. In Canada, adverse events to outpatient medications cause over two million emergency department visits and 700,000 hospital admissions, costing over $1 billion in healthcare expenditures annually. Optimizing the benefits of medications while limiting their potential for harm is a public health priority across patient populations, health settings and medical disciplines. The second most common subset of adverse events to outpatient medications was caused by non-adherence. Non-adherence has been associated with increased downstream health services utilization and costs of care, likely reflective of worse patient outcomes. It is unknown to what extent communication about non-adherence to outpatient medications can assist the care team in reinforcing patient adherence. Patients with adverse events due to non-adherence often seek care in hospitals due to the unexpected and serious nature of these events. After assessment and treatment, patients are discharged back into the care of a community-based provider who often cannot access the hospital's medical record, may not receive a legible or detailed discharge summary. Therefore, community-based care providers risk managing the patient without knowing about the patient's non-adherence, and inappropriately up-titrating medication doses, or simply missing an opportunity to emphasize the importance of adherence. The investigators developed ActionADE to address this type of information discontinuity. ActionADE was integrated to a province-wide network that links all pharmacies in British Columbia to a central data system, allowing users to see their patient's medication dispensing history. The investigators will conduct a triple-blind randomized controlled trial to evaluate the effectiveness of ActionADE on preventing subsequent non-adherence. The trial will take place in two urban tertiary care (Vancouver General and Saint Paul's Hospitals) and one urban community hospital (Lions Gate Hospital) within the Greater Vancouver area, in British Columbia, Canada. Other hospitals may be added to accelerate recruitment into the trial if approved by the British Columbia Ministry of Health. The primary objective of the trial is to evaluate the effect of providing information continuity about non-adherence using ActionADE on adherence over 12 months compared to standard care. Secondary objectives for both trials are to evaluate the effect on outpatient and emergency department visits, admissions, hospital-days and mortality.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 2000
Est. completion date July 31, 2024
Est. primary completion date July 31, 2022
Accepts healthy volunteers No
Gender All
Age group 19 Years and older
Eligibility Inclusion Criteria: - Adults 19 years of age or older presenting to the participating emergency departments with an adverse event due to non-adherence to a prescribed outpatient medication that was reported in ActionADE. Exclusion Criteria: - Patients whose adverse event is categorized as life threatening will be excluded. - Patients without a Provincial Health Number will be excluded as this will prevent linkage with PharmaNet and other administrative data for outcomes ascertainment. - Patients diagnosed with adverse drug events to culprit medications not on the provincial formulary will be excluded as we will not be able to ascertain re-dispensations outcomes for these medications using PharmaNet data.

Study Design


Related Conditions & MeSH terms


Intervention

Device:
ActionADE
ActionADE is a software application that allows healthcare providers to document standardized adverse drug event and non-adherence information in a user-friendly and standardized manner. We integrated ActionADE uni-directionally with PharmaNet, a secure province-wide network that links all pharmacies in British Columbia to a central data system. This allows care providers to pull in demographic information and visualize their patient's medication dispensing history. In 2020, we enabled bi-directional integration with PharmaNet allowing clinicians to transmit standardized information back to the PharmaNet database. The three dominant community pharmacy systems in the geographic area of the trial will display non-adherence information in their systems.

Locations

Country Name City State
n/a

Sponsors (4)

Lead Sponsor Collaborator
University of British Columbia Canadian Institutes of Health Research (CIHR), Ministry of Health, British Columbia, Vancouver Coastal Health

Outcome

Type Measure Description Time frame Safety issue
Primary Patient adherence to culprit medication We will define adherence as the dispensation of >80% of prescribed medication doses within 12-months, based on the recorded medication dose and frequency, and the volume and dates of re-dispensations. 12 months
Secondary Hospital visits Number of outpatient and emergency visits during the follow-up period. 12 months
Secondary Hospital stays Number of hospital-days during hospital admissions. 12 months
Secondary Mortality Number of all cause mortality over the follow-up period. 12 months
See also
  Status Clinical Trial Phase
Recruiting NCT03638726 - Subconjunctival Atropine and Intracameral Epinephrine for Pupil Dilation in Phacoemulsification Phase 4
Completed NCT05007041 - Simultaneous RZV and aIIV4 Vaccination Phase 4
Suspended NCT02559960 - Post-marketing Safety Surveillance of Breviscapine Powder-Injection : a Registry Study
Completed NCT05266300 - Implementation and Quality Assurance of DPYD-genotyping in Patients Treated With Fluoropyrimidines.
Completed NCT03112083 - Safety and Tolerability of Krill Powder Supplement in Slightly Overweight People With Moderately Elevated Blood Pressure N/A
Completed NCT05028361 - Simultaneous mRNA COVID-19 and IIV4 Vaccination Study Phase 4
Completed NCT04284553 - Optimizing Electronic Health Record Prompts With Behavioral Economics to Improve Prescribing for Older Adults N/A
Recruiting NCT06120712 - A Phase Ⅰb Study on Autologous GC101 TIL Injection for the Treatment of Advanced Melanoma (MIZAR-002) Phase 1/Phase 2
Completed NCT04181775 - Effectiveness of an ADE-related Hospitalization Risk Prediction Tool for Patients (ADE-RED)
Completed NCT02906657 - Medication Reconciliation Using Electronic Pharmaceutical Record: A Multicenter Study in the Hospitalized Elderly N/A
Completed NCT03640273 - Efficacy and Adverse Effects of Prapchompoothaweep Remedy and Loratadine for Treatment in AR Patients Phase 2
Completed NCT02162147 - How Safe Are Our Pediatric Emergency Departments? N/A
Completed NCT01897870 - The Effect of a Pharmacist Home Visit on Drug-related Problems Post-discharge. N/A
Completed NCT03725046 - Impact of an Optimized Communication on the Readmission for Adverse Drug Event N/A
Recruiting NCT04635956 - Camrelizumab Combined With Chemotherapy for Recurrent or Advanced Cervical Neuroendocrine Carcinomas Phase 2
Active, not recruiting NCT05538065 - NUDGE-EHR Replication Trial at Mass General Brigham N/A
Completed NCT03442010 - Adverse Drug Events at Emergency Department
Recruiting NCT04791150 - Rheumatologic Adverse Events and Cancer Immunotherapy N/A
Completed NCT02864030 - PAINTER: Polymorphism And INcidence of Toxicity in ERibulin Treatment Phase 4
Completed NCT03665402 - A Pharamcogenomic Study for Isoniazid According to NAT2 Polymorphism Status N/A